Starting insulin in type 2 diabetes: Overcoming barriers to insulin therapy

International Journal of Diabetes in Developing Countries

Volumn 28, Issue 2, 2008, Pages 65-68

  Kabadi, Udaya M ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Diabetes mellitus type 2; Dosage and schedules; Insulin; Oral hypoglycemic agents; Treatment

Indexed keywords

EID: 53849110919     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.4103/0973-3930.43102     Document Type: Review

References (21)

1. UKPDS Group. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995;44: 1249-58.
2. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig 1999;104:787-94.
3. Kabadi UM, Kabadi M. Early insulin secretion: Influence of insulin sensitivity. Diabetes Metab 2003;29:4S112.
4. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25: 1607-11.
5. Kabadi UM, Kabadi M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin Ther 2004;26:63-69.
6. Del Prato S, Vigili de Kreutzenberg S, Riccio A, Maifreni L, Duner E, Lisato G, et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (noninsulin dependent) diabetic subjects with secondary failure to oral agents. Diabetologia 1990;33:688-95.
7. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
8. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-59.
9. Skyler JS. Diabetic complications: The importance of glucose control. Endocrinol Metab Clin 1996;25:243-54.
10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000;321:405-12.
11. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20: 1847-53.
12. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28: 260-65.
13. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75-25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44.
14. Schreiber S, Schneider K, Schweitzer MA. The efficacy of longterm insulin glargine and oral antidiabetic therapy in patients with type 2 diabetes. Poster presented at 65th Scientific Sessions of the ADA; 2005. 579.
15. Hammer H, Schneider K, Niemoller E, Schweitzer MA. Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral agents on glycemic control in daily practice. Diabetes 2005;54:518.
16. Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28: 419-20.
17. Kabadi UM, Kabadi MU. Comparative efficacy of glimepiride and-or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 2006;72:265-70.
18. Rosenstock J. Insulin glargine plus oral agents vs. insulin detemir plus oral agents. Diabetes 2006;S1:555.
19. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.
20. Rosenstock J, Eihhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: A randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-57.
21. Kabadi UM. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents. Manag Care 2004;13: 48-9,53-6,58-9.